Content about biotechnology

November 23, 2011

British drug maker Shire is looking to make a biotech drug for a rare genetic disorder at a new manufacturing plant in Massachusetts.

LEXINGTON, Mass. — British drug maker Shire is looking to make a biotech drug for a rare genetic disorder at a new manufacturing plant in Massachusetts.

The company said Tuesday that it had filed with the Food and Drug Administration and the European Medicines Agency for approval to produce the Gaucher disease drug Vpriv (velaglucerase alfa) at its Lexington, Mass., plant. The company expects to win approval to make the drug there early next year.

November 22, 2011

Generic drug maker Par Pharmaceutical has promoted Thomas Haughey to president and Paul Campanelli to COO, the company said. The promotions take effect immediately.

WOODCLIFF LAKE, N.J. — Generic drug maker Par Pharmaceutical has promoted Thomas Haughey to president and Paul Campanelli to COO, the company said. The promotions take effect immediately.

"With the acquisition of Anchen and the pending acquisition of Edict, Par is becoming a larger and more complex organization with three diverse locations and more than 300 additional employees," Par chairman and CEO Patrick LePore said. "These new challenges and opportunities require a president and COO to effectively manage the company and its subsidiaries."

November 18, 2011

Par Pharmaceutical has completed its acquisition of Anchen Pharmaceuticals, the generic drug maker said.

WOODCLIFF LAKE, N.J. — Par Pharmaceutical has completed its acquisition of Anchen Pharmaceuticals, the generic drug maker said.

Par announced plans in August to acquire Irvine, Calif.-based Anchen for $410 million, consisting of a loan and cash it already had.

A privately owned company, Anchen has about 200 employees and more than 72,000 sq. ft. of manufacturing and warehouse space, Par said.

November 17, 2011

The increase in the number of people with rheumatoid arthritis, and the challenges posed to drug makers by generics, is encouraging the development of new drugs for the disease, according to a new report by Frost & Sullivan.

MOUNTAIN VIEW, Calif. — The increase in the number of people with rheumatoid arthritis, and the challenges posed to drug makers by generics, is encouraging the development of new drugs for the disease, according to a new report by Frost & Sullivan.

November 14, 2011

Celestial Seasonings has introduced an energy shot that combines B vitamins, botanicals and kombucha, a fermented black tea.

BOULDER, Colo. — Celestial Seasonings has introduced an energy shot that combines B vitamins, botanicals and kombucha, a fermented black tea.

Kombucha Energy Shots are packaged in single-serve, 2-fl.-oz. bottles and are available in citrus, berry and Pomegranate Xtreme varieties.

November 10, 2011

Biotechnology company Signum Biosciences has entered a collaborative agreement with GlaxoSmithKline whereby GSK will receive the exclusive right to Signum's proprietary phosphatase screening technology.

PRINCETON, N.J. — Biotechnology company Signum Biosciences has entered a collaborative agreement with GlaxoSmithKline whereby GSK will receive the exclusive right to Signum's proprietary phosphatase screening technology.

November 9, 2011

Diplomat Specialty Pharmacy was recognized by MichBio, a biosciences industry trade association and the official Michigan affiliate of the Biotechnology Industry Organization.

FLINT, Mich. — Diplomat Specialty Pharmacy was recognized by MichBio, a biosciences industry trade association and the official Michigan affiliate of the Biotechnology Industry Organization.

November 7, 2011

The Food and Drug Administration has approved a drug made by Bristol-Myers Squibb for treating head and neck cancer, the agency said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Bristol-Myers Squibb and Eli Lilly & Co. for treating head and neck cancer, the agency said Monday.

The FDA announced the approval of Erbitux (cetuximab) for use with chemotherapy in treating head and neck cancer that had spread to other parts of the body. The drug originally was approved in 2004 for treating certain cases of late-stage colon cancer in patients who had stopped responding to chemotherapy.

November 4, 2011

In the classic “Arabian Nights” tale of Aladdin and his magic lamp, the evil sorcerer who made Aladdin retrieve the lamp containing the genie attempts to get it back by tricking Aladdin’s wife into giving it to him by roaming through the streets offering to trade “new lamps for old.”


In the classic “Arabian Nights” tale of Aladdin and his magic lamp, the evil sorcerer who made Aladdin retrieve the lamp containing the genie attempts to get it back by tricking Aladdin’s wife into giving it to him by roaming through the streets offering to trade “new lamps for old.”


November 4, 2011

In September, the Generic Pharmaceutical Association announced the appointment of Ralph Neas — former president and CEO of the National Coalition on Health Care — as its new president and CEO, replacing Kathleen Jaeger, who stepped down as president and CEO of the organization in May 2010.

In September, the Generic Pharmaceutical Association announced the appointment of Ralph Neas — former president and CEO of the National Coalition on Health Care — as its new president and CEO, replacing Kathleen Jaeger, who stepped down as president and CEO of the organization in May 2010. Drug Store News recently spoke with Neas about his plans and vision for the organization and the industry as a whole.


October 31, 2011

Watson Pharmaceuticals and a partnering company are barred from launching a generic version of a blood-thinning drug under a federal court decision issued Friday.

PARSIPPANY, N.J. — Watson Pharmaceuticals and a partnering company are barred from launching a generic version of a blood-thinning drug under a federal court decision issued Friday.

October 28, 2011

EO Products, a manufacturer of natural and organic body care, has announced that its entire line of soaps and lotions has received NON-GMO verification from the NON-GMO Project.

CORTE MADERA, Calif. — EO Products, a manufacturer of natural and organic body care, has announced that its entire line of soaps and lotions has received NON-GMO verification from the NON-GMO Project.

The Non-GMO Project offers third-party verification for products produced according to rigorous best practices for GMO (genetically modified organism) avoidance.

October 3, 2011

Pharmacy benefit manager Express Scripts has launched a suite of services for drug makers through HealthBridge Pharma & Biotech to provide a single-solution approach to patient care.

ST. LOUIS — Pharmacy benefit manager Express Scripts has launched a suite of services for drug makers through HealthBridge Pharma & Biotech to provide a single-solution approach to patient care.

September 27, 2011

AmerisourceBergen on Tuesday purchased TheraCom, a subsidiary of CVS Caremark that provides a wide range of support to pharmaceutical and biotechnology drug manufacturers, including consulting and reimbursement services, for $250 million.

VALLEY FORGE, Pa. — AmerisourceBergen on Tuesday purchased TheraCom, a subsidiary of CVS Caremark that provides a wide range of support to pharmaceutical and biotechnology drug manufacturers, including consulting and reimbursement services, for $250 million.

TheraCom is a provider of commercialization support services to the biotech and pharmaceutical industry, specifically, providing reimbursement and patient access support services, and will join Lash Group as part of AmerisourceBergen Consulting Services.

September 12, 2011

It’s hard to disagree that generic drug companies have had a good run for the last several years. Branded drug companies developed a large number of drugs that proved highly effective at treating widespread medical conditions and became blockbusters, garnering billions of dollars in sales in the United States alone.

It’s hard to disagree that generic drug companies have had a good run for the last several years. Branded drug companies developed a large number of drugs that proved highly effective at treating widespread medical conditions and became blockbusters, garnering billions of dollars in sales in the United States alone. As patents on these blockbuster drugs have expired, they’ve provided generic manufacturers with enormous revenues, helping some to join the ranks of the world’s biggest drug companies.


September 12, 2011

At press time, Hurricane Irene was slowly barreling toward the East Coast and threatening the area with a deluge that prompted cities to shut down and had store shelves wiped clean.


At press time, Hurricane Irene was slowly barreling toward the East Coast and threatening the area with a deluge that prompted cities to shut down and had store shelves wiped clean.


September 1, 2011

The Food and Drug Administration has approved a new use for a follow-on biologic made by Sandoz.

PRINCETON, N.J. — The Food and Drug Administration has approved a new use for a follow-on biologic made by Sandoz.

Sandoz, the generic drugs arm of Swiss drug maker Novartis, announced the approval of Omnitrope (somatropin [rDNA origin]) for children with growth failure due to Turner syndrome. Sandoz said Omnitrope was now approved for all the same indications as the reference product, Pfizer's Genotropin.

August 24, 2011

The final outcome of the battle between Israel’s Teva Pharmaceutical Industries and Canada’s Valeant Pharmaceuticals International to buy Cephalon serves as a good illustration of why it helps to have a plan B.


The final outcome of the battle between Israel’s Teva Pharmaceutical Industries and Canada’s Valeant Pharmaceuticals International to buy Cephalon serves as a good illustration of why it helps to have a plan B.


In May, Teva beat out Valeant’s $5.7 billion offer to buy Frazier, Pa.-based Cephalon with a $6.8 billion offer of its own, acquiring Cephalon’s hefty pipeline in the process. And last month, Teva bought Taiyo Pharmaceutical Industry, Japan’s third-largest generics company, for $934 million.


August 18, 2011

With the global biosimilars market expected to expand nearly sixfold by the middle of the decade, market research firm IMS Health is launching a market-measurement tool for drug makers interested in getting into the space, the company said.

DANBURY, Conn. — With the global biosimilars market expected to expand nearly sixfold by the middle of the decade, market research firm IMS Health is launching a market-measurement tool for drug makers interested in getting into the space, the company said.

August 2, 2011

The VP distribution operations for Omnicare's RxCrossroads business has stepped into a new role, Omnicare announced Tuesday.

COVINGTON, Ky. — The VP distribution operations for Omnicare's RxCrossroads business has stepped into a new role, Omnicare announced Tuesday.

Dan Thomas was appointed to the role of SVP and general manager for RxCrossroads, an Omnicare division that provides specialized solutions specifically tailored to the biotechnology and pharmaceutical industries. Thomas, who has worked in the unit for 27 years, will have full operational responsibility in his new role and report to Nitin Sahney, EVP and president of Omnicare’s Specialty Care Group.

July 28, 2011

The president and CEO of Sanofi's U.S. operations is stepping into a newly created role at the drug maker.

PARIS — The president and CEO of Sanofi's U.S. operations is stepping into a newly created role at the drug maker.

Greg Irace will become SVP global services, leading the global information systems function and will be responsible for shared support functions across all Sanofi businesses in North America. He also will play a key role in the development of a global strategy for shared services. Irace will report to Jérôme Contamine, Sanofi EVP and CFO.

June 28, 2011

Generic drug maker Hi-Tech Pharmacal said that it has acquired marketing and distribution rights to pain treatments made by Atley Pharmaceuticals.

AMITYVILLE, N.Y. — Generic drug maker Hi-Tech Pharmacal said that it has acquired marketing and distribution rights to pain treatments made by Atley Pharmaceuticals.

Hi-Tech, which paid $3.6 million in cash for rights to the products and inventory, said some of Atley's drugs already have been approved by the Food and Drug Administration, while others were pending approval. The company didn't say which products it was acquiring the rights to, but noted that Hi-Tech subsidiary ECR Pharmaceuticals will produce and promote the products.

June 28, 2011

Eli Lilly will invest funds into its existing biotechnology capabilities to further research and development of multispecific therapeutics.

WASHINGTON — Eli Lilly will invest funds into its existing biotechnology capabilities to further research and development of multispecific therapeutics.

June 20, 2011

A panel of Food and Drug Administration experts has recommended approval of an investigational biotech drug made by Regeneron Pharmaceuticals for eye diseases.

TARRYTOWN, N.Y. — A panel of Food and Drug Administration experts has recommended approval of an investigational biotech drug made by Regeneron Pharmaceuticals for eye diseases.

Regeneron said Friday that the FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee unanimously recommended approval of Eylea (aflibercept) ophthalmic solution for the treatment of a form of age-related macular degeneration, also known as wet AMD. The disease causes abnormal growth of new blood vessels in the eye.

June 20, 2011

The overall growth in drug spending for 2010 was 3.7%, according to the latest drug trend report by pharmacy benefit manager Medco Health Solutions. The lower increase 
was primarily due to higher rates of generic drug dispensing — more than 71% of drugs dispensed were generics.